Cargando…
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
INTRODUCTION: Few studies have compared adherence between long-acting injectable antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (AOM 400; aripiprazole monohydrate) and oral antipsychotics, in patients with schizophrenia or bipolar I disorder (BD-I) in a real-world...
Autores principales: | Yan, Tingjian, Greene, Mallik, Chang, Eunice, Hartry, Ann, Touya, Maëlys, Broder, Michael S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182631/ https://www.ncbi.nlm.nih.gov/pubmed/30206822 http://dx.doi.org/10.1007/s12325-018-0785-y |
Ejemplares similares
-
F75. MEDICATION ADHERENCE AND DISCONTINUATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE ONCE-MONTHLY LONG-ACTING INJECTABLE VERSUS THOSE TREATED WITH ORAL ANTIPSYCHOTICS
por: Greene, Mallik, et al.
Publicado: (2018) -
O8.5. SCHIZOPHRENIA AND BIPOLAR DISORDER DIAGNOSIS PATTERNS: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018) -
Effect of aripiprazole once-monthly 400mg (AOM400) on hospitalisation prevention and use of healthcare resources in schizophrenia patients, a study based on real clinical practice on schizophrenia: AMBITION Study
por: Sanchez-Gistau, V., et al.
Publicado: (2023) -
Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data
por: Yermilov, Irina, et al.
Publicado: (2018) -
S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)